Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus.
Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus.
复制标题
DOI：
10.4103/2230-8210.77571
复制
发表时间：
2011-01
影响因子：
--
通讯作者：
Baruah MP
中科院分区：
文献类型：
--
作者：
Dharmalingam M;Sriram U;Baruah MP
2型糖尿病（T2 DM）是一种与显著发病率和死亡率相关的进行性疾病。尽管在2型糖尿病的管理方面已经取得了进展，但目前对这种疾病患者的治疗偏好仍然不足以解决疾病进展。采用本疗法，血糖控制仍然不理想，并且通常与体重增加和低血糖相关。胰高血糖素样肽-I（GLP-1）是从小肠分泌的肠降血糖素激素，其通过多种机制降低空腹和餐后葡萄糖，所述机制包括葡萄糖依赖性胰岛素分泌、胰高血糖素分泌减少、延迟胃排空和增加饱腹感。利拉鲁肽是一种人胰高血糖素样肽1（GLP-1）类似物，是一种治疗T2 DM的药物，每日一次皮下注射给药。在利拉鲁肽对糖尿病的效应和作用（LEAD）III期临床试验项目中，研究了利拉鲁肽0.6、1.2和1.8 mg剂量与其他T2 DM治疗联合治疗T2 DM的疗效和耐受性，并与其他T2 DM治疗进行了比较。在LEAD试验中，利拉鲁肽治疗与血糖控制显著改善和低血糖风险降低相关。此外，利拉鲁肽显著改善β细胞功能，降低收缩压（BP）并诱导体重减轻。总体而言，利拉鲁肽耐受性良好。来自现实临床实践环境的利拉鲁肽安全性和疗效的最新数据也重申了该分子的更佳治疗特征。根据LEAD项目的结果和实际临床经验，利拉鲁肽已被证明是一种有效的治疗干预措施，即使在糖尿病的早期阶段，无论使用何种药物。
Type 2 diabetes mellitus (T2DM) is a progressive disease associated with significant morbidity and mortality. Even though progress have been accomplished in the management of type 2 diabetes, current treatment preferences for patients with this disease still fall short to address disease progression. With the present therapy, glycaemic control remains suboptimal and are often associated with weight gain and hypoglycaemia. Glucagon like peptide-1 (GLP-1) is an incretin hormone secreted from the small intestine that lowers fasting and postprandial glucose through multiple mechanisms including glucose-dependent insulin secretion, reduction of glucagon secretion, delaying gastric emptying and increased satiety. Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue is a treatment for T2DM that is administered as a once-daily subcutaneous injection. The efficacy and tolerability of liraglutide at doses of 0.6, 1.2, and 1.8 mg for T2DM, in combination with, and compared with, other T2DM treatments were investigated in the Liraglutide Effect and Action in Diabetes (LEAD) Phase III clinical trial program. In the LEAD trial, treatment with liraglutide was associated with substantial improvements in glycaemic control and low risk of hypoglycaemia. In addition liraglutide significantly improved β-cell function, reduced systolic blood pressure (BP) and induced weight loss. Overall, liraglutide was well tolerated. Recent data on safety and efficacy of liraglutide from real-life clinical practice settings also reiterate the better therapeutic profile of this molecule. Based on results from the LEAD programme, and real-life clinical experience, liraglutide has been demonstrated as an effective therapeutic intervention even at the early stage of diabetes regardless of with what, it has been used.